The APOL1 and Adult Kidney Disease Laboratory investigates the molecular and translational biology of APOL1-associated nephropathy, with a particular focus on the mechanisms through which APOL1 genetic variation contributes to kidney disease susceptibility and progression.
Variants within the APOL1 locus represent one of the most significant genetic determinants of kidney disease identified to date and are strongly associated with increased risk for focal segmental glomerulosclerosis, hypertensive nephropathy, HIV-associated nephropathy, and progressive CKD. However, despite the magnitude of their clinical impact, the biological mechanisms linking APOL1 risk alleles to renal injury remain incompletely understood.
A central goal of the laboratory is therefore to define how APOL1 risk variants perturb cellular homeostasis and drive kidney pathology at the molecular level. We investigate how APOL1 risk variants alter cellular physiology and promote cytotoxicity, as well as how protective variants may attenuate pathogenic signaling or preserve cellular resilience under stress conditions.
An additional major focus concerns the broader APOL protein family and the extent to which functional interactions among APOL family members influence APOL1 behavior and disease expression. These studies aim to understand APOL1 not as an isolated pathogenic factor, but rather within the context of a coordinated and evolutionarily shaped biological network whose regulation may critically determine renal outcome.
The laboratory combines mechanistic experimental approaches with translational and population-level investigations. Experimental findings derived from cellular and molecular systems are systematically integrated with data from clinically characterized patient cohorts to establish direct connections between mechanistic biology and human disease manifestation. This includes studies of disease penetrance, ancestry-associated genetic architecture, modifier loci, and environmental determinants of renal risk.
A defining strength of the laboratory is its extensive international collaborative framework involving investigators and patient cohorts across the United States and multiple African countries. These collaborations enable large-scale population genetics analyses in ancestrally relevant populations enriched for APOL1 risk alleles and provide a critical translational dimension to the laboratory’s work.
Through these efforts, the laboratory seeks to bridge molecular nephrology, evolutionary genetics, and clinical epidemiology in order to develop a more integrated understanding of APOL1-mediated disease.